Adding investigational anifrolumab to standard therapy lowers disease activity, limits the need for corticosteroids, and eases skin symptoms in people with moderate to severe systemic lupus erythematosus (SLE), a Phase 3 clinical trial shows. Trial results were discussed in a presentation titled “A Phase 3…

Corticosteroids and hydroxychloroquine are the most common medications used by patients with systemic lupus erythematosus (SLE) or lupus nephritis (LN), according to a real-world study, which also found very limited use of biologics. The study, “Real World Medication Use in Incident Systemic Lupus Erythematosus and…

Some of you will remember the 1980s public service commercial where the man holds an egg in his hand and says, “This is your brain.” He then cracks it into a sizzling cast iron pan and says, “This is your brain on drugs. Any questions?” I’m not sure…

Early treatment to reduce disease activity and prevent irreversible organ damage in pediatric systemic lupus erythematosus (pSLE) patients should be strongly considered, according to new study. The research, “Pediatric Systemic Lupus Erythematosus: Learning From Longer Follow Up to Adulthood,” appeared in the journal Frontiers in…

Treatment with H.P. Acthar Gel (repository corticotropin injection) can effectively help manage systemic lupus erythematosus (SLE) symptoms in patients with persistently active disease, according to recent Phase 4 clinical data. The study, “Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc…

Approximately one-third of patients with systemic lupus erythematosus (SLE) admit to self-managing their corticosteroid medication without the consent of their rheumatologist or healthcare provider (HCP). The findings, which stem from the multi-country GSK suvey called EnABLE, highlight the need for a more proactive approach in lupus management, and improved awareness…

GlaxoSmithKline’s Benlysta reduced lupus patients’ need for higher doses of corticosteroids, a therapy that is beneficial but causes long-term organ damage, an additional analysis of Phase 3 clinical trial results shows. In addition, a combination of Benlysta and corticosteroids reduced patients’ organ damage more than corticosteroids alone over five years, two extensions…

New mothers with systemic lupus erythematosus (SLE) are less likely to breastfeed their infants, or to do so for a shorter span of time, than are woman without this disease — despite guidelines favoring breastfeeding throughout a baby’s first months of life, a study in Argentina reports. The study, “…

Treating newly diagnosed systemic lupus erythematosus patients with Rituxan (rituximab) is safe and effective, according to a study that followed a small group of patients over several years. A key finding was that Rituxan reduced the patients’ use of corticosteroids, which is good news because long-term steroid use can cause numerous…

In this short video from Corbus Pharmaceutical Holdings Ltd, Dr. Meggan Mackay from the Hofstra Northwell School of Medicine in Hempstead, New York, tells us a little bit about how Resunab is different than other treatments for lupus. Read how Corbus added a clinical protocol to a lupus Phase…